Evidence map›Paper›PMID 29299955›Full record

ArticleRenal failure2018

Apocynin combined with drugs as coadjuvant could be employed to prevent and/or treat the chronic kidney disease.

Jorge Osvaldo Montes-Rivera, Feliciano Tamay-Cach, Julio César Quintana-Pérez, Juan Alberto Guevara-Salazar, José Guadalupe Trujillo-Ferrara, Leonardo Del Valle-Mondragón, Mónica Griselda Arellano-Mendoza

Open access · goldAbstract readComparative Study
In one paragraph

Article in Renal failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jorge Osvaldo Montes-Riveraa Laboratorio de Investigación en Enfermedades Crónico Degenerativas, Sección de Estudios de Posgrado e Investigación, Departamento de Formación Básica Disciplinaria, Escuela Superior de Medicina , Instituto Politécnico Nacional , Ciudad de México , México.
Feliciano Tamay-Cachb Sección de Estudios de Posgrado e Investigación, Departamento de Formación Básica Disciplinaria, Escuela Superior de Medicina , Instituto Politécnico Nacional , Ciudad de México , México.
Julio César Quintana-Pérezb Sección de Estudios de Posgrado e Investigación, Departamento de Formación Básica Disciplinaria, Escuela Superior de Medicina , Instituto Politécnico Nacional , Ciudad de México , México.
Juan Alberto Guevara-Salazarb Sección de Estudios de Posgrado e Investigación, Departamento de Formación Básica Disciplinaria, Escuela Superior de Medicina , Instituto Politécnico Nacional , Ciudad de México , México.
José Guadalupe Trujillo-Ferrarab Sección de Estudios de Posgrado e Investigación, Departamento de Formación Básica Disciplinaria, Escuela Superior de Medicina , Instituto Politécnico Nacional , Ciudad de México , México.
Leonardo Del Valle-Mondragónc Departamento de Farmacología , Instituto Nacional de Cardiología "Ignacio Chavéz" , Ciudad de México , México.
Mónica Griselda Arellano-Mendozaa Laboratorio de Investigación en Enfermedades Crónico Degenerativas, Sección de Estudios de Posgrado e Investigación, Departamento de Formación Básica Disciplinaria, Escuela Superior de Medicina , Instituto Politécnico Nacional , Ciudad de México , México.
Instituto Politécnico Nacional · MXInstituto Nacional de Cardiología · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A worldwide public health problem is chronic kidney disease (CKD) presenting alarming epidemiological data. It currently affects about 10% of the adult population worldwide and has a high mortality rate. It is now known that oxidative stress represents one of the most important mechanisms in its pathophysiology, from the early stages to the terminal phase. Oxidation increases inflammation and reduces the capacity of NO

Indexed as

AcetophenonesAdjuvants, PharmaceuticAnimalsAntihypertensive AgentsAntioxidantsBlood PressureCaptoprilDisease Models, AnimalDisease ProgressionDrug SynergismDrug Therapy, CombinationEndothelium, VascularHumansLosartanMiceMice, Inbred C57BLAcetophenonesacetovanilloneAdjuvants, PharmaceuticAntihypertensive AgentsAntioxidantsCaptoprilLosartanApocyninchronic renal failureendothelial dysfunctionnephrectomyoxidative stress

Identifiers

PMID29299955
PMCPMC6014519
OpenAlexW2782210075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.